tradingkey.logo
tradingkey.logo
Search

Nuwellis Inc

NUWE
Add to Watchlist
0.995USD
-0.045-4.33%
Close 05/15, 16:00ETQuotes delayed by 15 min
2.67MMarket Cap
0.73P/E TTM

Nuwellis Inc

0.995
-0.045-4.33%
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison

TradingKey Stock Score of Nuwellis Inc

Currency: USD Updated: 2026-05-15

Key Insights

Nuwellis Inc's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is significant.Its valuation is considered fairly valued, ranking 150 out of 206 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Hold, with the highest price target at 11.00.In the medium term, the stock price is expected to trend down.The company has shown weak stock market performance over the past month, in line with its weak fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Nuwellis Inc's Score

Industry at a Glance

Industry Ranking
150 / 206
Overall Ranking
416 / 4482
Industry
Healthcare Equipment & Supplies

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Media Coverage

Last 24 hours
Coverage Level

Very Low
Very High
Neutral

Nuwellis Inc Highlights

StrengthsRisks
Nuwellis, Inc. is a commercial-stage medical technology company. The Company is focused on developing, manufacturing, and commercializing medical devices used in ultrafiltration therapy, including the Aquadex FlexFlow and the Aquadex SmartFlow systems (collectively the Aquadex System). The Aquadex SmartFlow system is indicated for temporary or extended use in adult and pediatric patients weighing 20 kilograms or more whose fluid overload is unresponsive to medical management, including diuretics. The Aquadex System is designed to remove excess fluid from patients suffering from fluid overload who have failed diuretic therapy. The Aquadex System consists of a console, which is a piece of equipment containing electromechanical pumps and a liquid crystal display (LCD) screen; a one-time disposable blood circuit set, which is an integrated collection of tubing, filters, sensors, and connectors that contain and deliver the blood from and back to the patient, and a disposable catheter.
Growing
The company is in a growing phase, with the latest annual income totaling USD 8.27M.
Overvalued
The company’s latest PE is 0.73, at a high 3-year percentile range.
Institutional Buying
The latest institutional holdings are 135.71K shares, increasing 30.29% quarter-over-quarter.
Held by James Simons
Star Investor James Simons holds 0.00 shares of this stock.

Analyst Rating

Based on 1 analysts
Hold
Current Rating
11.000
Target Price
+4890.93%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-05-15

The current financial score of Nuwellis Inc is 5.22, ranking 201 out of 206 in the Healthcare Equipment & Supplies industry. Its financial status is stable, and its operating efficiency is low. Its latest quarterly revenue reached 2.40M, representing a year-over-year increase of 26.21%, while its net profit experienced a year-over-year increase of 50.65%.

Score

Industry at a Glance

Previous score
5.22
Change
0

Financials

7.90

Key Metrics

Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.

Quality of Earnings

2.38

Operational Efficiency

2.84

Growth Potential

5.91

Shareholder Returns

7.08

Nuwellis Inc's Company Valuation

Currency: USD Updated: 2026-05-15

The current valuation score of Nuwellis Inc is 7.68, ranking 67 out of 206 in the Healthcare Equipment & Supplies industry. Its current P/E ratio is 0.73, which is 0.00% below the recent high of 0.73 and 138.39% above the recent low of -0.28.

Score

Industry at a Glance

Previous score
7.68
Change
0

Valuation Dimensions

P/E
P/B
P/S
P/CF
Industry Ranking 150/206
Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-05-15

The current earnings forecast score of Nuwellis Inc is 6.00, ranking 175 out of 206 in the Healthcare Equipment & Supplies industry. The average price target is 11.00, with a high of 11.00 and a low of 11.00.

Score

Industry at a Glance

Previous score
6.00
Change
0

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 1 analysts
Hold
Current Rating
11.000
Target Price
+4890.93%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell

Peer Comparison

93
Total
4
Median
7
Average
Company name
Ratings
Analysts
Nuwellis Inc
NUWE
1
Boston Scientific Corp
BSX
37
Intuitive Surgical Inc
ISRG
35
Edwards Lifesciences Corp
EW
35
Veeva Systems Inc
VEEV
30
Thermo Fisher Scientific Inc
TMO
30
1
2
3
...
19

Financial Forecasting

EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-05-15

The current price momentum score of Nuwellis Inc is 1.84, ranking 201 out of 206 in the Healthcare Equipment & Supplies industry. Currently, the stock price is trading between the resistance level at 1.15 and the support level at 0.91, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score
1.84
Change
0

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators

The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators
Sell(3)
Neutral(1)
Buy(0)
Indicators
Value
Direction
MACD(12,26,9)
-0.009
Sell
RSI(14)
32.244
Neutral
STOCH(KDJ)(9,3,3)
15.692
Oversold
ATR(14)
0.077
Low Volatility
CCI(14)
-120.886
Sell
Williams %R
93.182
Oversold
TRIX(12,20)
-0.430
Sell
StochRSI(14)
0.000
Oversold
Moving Average
Sell(6)
Neutral(0)
Buy(0)
Indicators
Value
Direction
MA5
1.023
Sell
MA10
1.062
Sell
MA20
1.101
Sell
MA50
1.131
Sell
MA100
1.667
Sell
MA200
2.706
Sell

Institutional Confidence

Currency: USD Updated: 2026-05-15

The current institutional shareholding score of Nuwellis Inc is 3.00, ranking 133 out of 206 in the Healthcare Equipment & Supplies industry. The latest institutional shareholding proportion is 6.78%, representing a quarter-over-quarter decrease of 16.38%. The largest institutional shareholder is James Simons, holding a total of 0.00 shares, representing 0.00% of shares outstanding, with 1.00% increase in holdings.

Score

Industry at a Glance

Previous score
3.00
Change
0

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name
Shares Held
Chg %
Sabby Management, LLC
89.69K
+149.86%
DRW Securities, LLC
17.66K
-51.05%
Geode Capital Management, L.L.C.
10.36K
--
XTX Markets LLC
10.19K
--
Bigger Capital Funds, LP
5.69K
--
Citi Investment Research (US)
3.00
-99.74%
Tower Research Capital LLC
1.99K
+93.50%
Erb (John L)
803.00
--
SBI Securities Co., Ltd.
63.00
--
UBS Financial Services, Inc.
578.00
-79.78%
1
2

Risk Assessment

Currency: USD Updated: 2026-05-15

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Healthcare Equipment & Supplies domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Nuwellis Inc is 1.92, ranking 170 out of 206 in the Healthcare Equipment & Supplies industry. The company's beta value is 0.26. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.

Score

Industry at a Glance

Previous score
1.92
Change
0
Beta vs S&P 500 index
0.25
VaR
+13.04%
240-Day Maximum Drawdown
+97.20%
240-Day Volatility
+197.39%

Return

Best Daily Return
60 days
+10.60%
120 days
+78.14%
5 years
--
Worst Daily Return
60 days
-9.79%
120 days
-22.37%
5 years
-100.00%
Sharpe Ratio
60 days
-3.78
120 days
-0.51
5 years
--

Risk Assessment

Maximum Drawdown
240 days
+97.20%
3 years
+99.97%
5 years
+99.99%
Return-to-Drawdown Ratio
240 days
-1.00
3 years
-0.33
5 years
-0.20
Skewness
240 days
+5.36
3 years
--
5 years
--

Volatility

Realised Volatility
240 days
+197.39%
5 years
+245.68%
Standardised True Range
240 days
+68.79%
5 years
+25746.53%
Downside Risk-Adjusted Return
120 days
-106.82%
240 days
-106.82%
Maximum Daily Upside Volatility
60 days
+61.69%
Maximum Daily Downside Volatility
60 days
+53.57%

Liquidity

Average Turnover Rate
60 days
+490.24%
120 days
+9471.34%
5 years
--
Turnover Deviation
20 days
-90.57%
60 days
-87.06%
120 days
+150.02%

Peer Comparison

Healthcare Equipment & Supplies
Nuwellis Inc
Nuwellis Inc
NUWE
4.52 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Lantheus Holdings Inc
Lantheus Holdings Inc
LNTH
8.68 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Anika Therapeutics Inc
Anika Therapeutics Inc
ANIK
8.58 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
LivaNova PLC
LivaNova PLC
LIVN
8.37 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Thermo Fisher Scientific Inc
Thermo Fisher Scientific Inc
TMO
8.35 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Bruker Corp
Bruker Corp
BRKR
8.23 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
KeyAI